Morgan Stanley: Medicis Pharmaceuticals' 4Q Slightly Above Consensus


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


In a research report published today, Morgan Stanley said Medicis Pharmaceutical's (NYSE: MRX) 4Q results included operating margin upside partially offset by an unusually high tax rate.According to Morgan Stanley, “Revenues were $181M, in line with our $179M and cons' $180M. EPS were $0.56, 5% above our $0.53 and cons' $0.55. Note MRX excluded $8.9M amort. expense (both original MRX amort + new Graceway amort.) from non-GAAP EPS (as planned). Operating margin was 36.6% vs. our 29.8% estimate. Tax rate was 49.4% vs. our 39.5% estimate due to one-time Graceway acq. taxes.” Morgan Stanley maintains its Equal-weight rating on Medicis Pharmaceuticals, which closed yesterday at $33.81.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorReiterationAnalyst RatingsMorgan Stanley